Fig. 2From: Microvesicle-camouflaged biomimetic nanoparticles encapsulating a metal-organic framework for targeted rheumatoid arthritis therapyIn vitro cumulative release of various formulations at (A) pH 7.4 and (B) pH 5.0. Data are shown as mean ± SD (n = 3). FPD: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate (polyethylene glycol)-2000; MTX: methotrexate; MV: microvesicle; ZIF-8: zeolitic imidazolate framework-8Back to article page